Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients

Table 1 General demographic

		N = 37	%
Age, median (IQR)		61 (58–68)
Male		13	35
Smoking history		6	16
Karnofsky performance scale	> 80	22	59
	70–80	13	35
	< 70	2	5
Initial stage	I	5	14
	II	2	5
	III	13	35
	IV	17	46
EGFR mutation	Del 19	11	30
	L858R	23	62
	Others	3	8
Pathology	Adenocarcinoma	37	100
Tumor number	1	13	35
	2–3	24	65
Main tumor location	Supratentorial	30	81
	Infratentorial	7	19
Treatment	Surgery	21	57
	WBRT	16	43
Subsequent therapy	Change TKI	24	65
	Keep TKI	8	22
	Chemotherapy	5	14
Oligoprogression type	Repeat or Metachronous	17	46
	Induced	20	54

Del 19, exon 19 deletion; L858R, exon 21 L858R; Others, Exon 21 L861Q, Exon 18 G719X, and Exon 20 S768I; IQR, interquartile range; TKI, tyrosine kinase inhibitors; WBRT, whole brain radiation therapy

ISSN: 1477-7819